CJC-1295 / Ipamorelin Blend
GHRH Analog + GHRP Combination Blend
This research blend combines CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH), with Ipamorelin, a selective growth hormone secretagogue receptor (GHSR) agonist. The combination is studied for its complementary mechanisms of action on the somatotropic axis. CJC-1295 extends the half-life of endogenous GHRH signaling while Ipamorelin selectively stimulates GH release with minimal effect on cortisol or prolactin, making this blend a useful tool for studying GH pulsatility and downstream IGF-1 signaling in research models.
Product Specifications
Store lyophilized at -20°C. Reconstituted solution stable at 4°C for up to 7 days.
≥98% by HPLC
Lyophilized Blend
Research Notes
Mechanism of Action
CJC-1295 binds and activates GHRH receptors on pituitary somatotrophs, amplifying GH pulse amplitude. Ipamorelin acts as a ghrelin mimetic at GHSR-1a, stimulating GH release through a distinct pathway. Together they produce synergistic GH secretagogue activity in research models.
Research Use Only. This product is intended solely for in-vitro research and laboratory use by qualified researchers. It is not approved for human or animal consumption, therapeutic use, or diagnostic application. By purchasing, you confirm compliance with all applicable laws and regulations.
Also Available